Arcturus Therapeutics Holdings Inc (ARCT)
18.34
-0.84
(-4.38%)
USD |
NASDAQ |
Nov 14, 16:00
18.26
-0.08
(-0.44%)
After-Hours: 07:32
Arcturus Therapeutics Holdings Research and Development Expense (Quarterly): 39.13M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 39.13M |
| June 30, 2024 | 58.67M |
| March 31, 2024 | 53.57M |
| December 31, 2023 | 36.62M |
| September 30, 2023 | 51.08M |
| June 30, 2023 | 52.67M |
| March 31, 2023 | 51.77M |
| December 31, 2022 | 26.98M |
| September 30, 2022 | 37.69M |
| June 30, 2022 | 38.19M |
| March 31, 2022 | 44.89M |
| December 31, 2021 | 32.63M |
| September 30, 2021 | 45.40M |
| June 30, 2021 | 45.68M |
| March 31, 2021 | 50.05M |
| December 31, 2020 | 24.29M |
| September 30, 2020 | 17.70M |
| June 30, 2020 | 7.944M |
| March 31, 2020 | 7.917M |
| December 31, 2019 | 11.99M |
| September 30, 2019 | 7.053M |
| June 30, 2019 | 7.269M |
| March 31, 2019 | 7.324M |
| December 31, 2018 | 4.847M |
| September 30, 2018 | 3.969M |
| Date | Value |
|---|---|
| June 30, 2018 | 4.225M |
| March 31, 2018 | 3.941M |
| December 31, 2017 | 4.353M |
| September 30, 2017 | 3.563M |
| June 30, 2017 | 3.769M |
| March 31, 2017 | 2.06M |
| December 31, 2016 | 3.99M |
| September 30, 2016 | 6.40M |
| June 30, 2016 | 4.182M |
| March 31, 2016 | 3.362M |
| December 31, 2015 | -4.65M |
| September 30, 2015 | 2.853M |
| June 30, 2015 | 3.683M |
| March 31, 2015 | 3.59M |
| December 31, 2014 | 4.908M |
| September 30, 2014 | 8.757M |
| June 30, 2014 | 5.918M |
| March 31, 2014 | 5.522M |
| December 31, 2013 | 4.603M |
| September 30, 2013 | 2.067M |
| June 30, 2013 | 0.321M |
| March 31, 2013 | 0.075M |
| December 31, 2012 | 0.067M |
| September 30, 2012 | 0.119M |
| June 30, 2012 | 0.231M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.917M
Minimum
Mar 2020
58.67M
Maximum
Jun 2024
36.74M
Average
38.66M
Median
Research and Development Expense (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | 17.26M |
| Bioventus Inc | 3.808M |
| Liquidia Corp | 9.42M |
| Pfizer Inc | 2.598B |
| AIM ImmunoTech Inc | 1.145M |